Patents by Inventor Mayland Chang
Mayland Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170274053Abstract: The invention provides compounds, compositions, and methods to improve or accelerate the healing of a wound. In various embodiments, the methods can include the topical treatment of the wound with the enzyme MMP-8, or the topical treatment of the wound with MMP-8 in combination with administration of an MMP-9 inhibitor, to accelerate the healing of the wound.Type: ApplicationFiled: September 21, 2015Publication date: September 28, 2017Applicant: University of Notre Dame du LacInventors: Mayland CHANG, Shahriar MOBASHERY
-
Publication number: 20170190685Abstract: The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The compounds can be selective MMP inhibitors, for example, selective inhibitors of MMP-2, MMP-9, and/or MMP-14. The disease, disorder, or condition can include, for example, stroke, neurological disorders, ophthalmological disorders, or wounds, such as chronic wounds or diabetic wounds.Type: ApplicationFiled: March 24, 2017Publication date: July 6, 2017Applicant: University of Notre Dame du LacInventors: Mayland CHANG, Shahriar MOBASHERY
-
Patent number: 9604957Abstract: The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The compounds can be selective MMP inhibitors, for example, selective inhibitors of MMP-2, MMP-9, and/or MMP-14. The disease, disorder, or condition can include, for example, stroke, neurological disorders, ophthalmological disorders, or wounds, such as chronic wounds or diabetic wounds.Type: GrantFiled: February 20, 2015Date of Patent: March 28, 2017Assignee: University of Notre Dame du LacInventors: Mayland Chang, Shahriar Mobashery
-
Publication number: 20170015647Abstract: The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The compounds can be selective MMP inhibitors, for example, selective inhibitors of MMP-2, MMP-9, and/or MMP-14. The disease, disorder, or condition can include, for example, stroke, neurological disorders, ophthalmological disorders, or wounds, such as chronic wounds or diabetic wounds.Type: ApplicationFiled: February 20, 2015Publication date: January 19, 2017Applicant: University of Notre Dame du LacInventors: Mayland CHANG, Shahriar MOBASHERY
-
Publication number: 20160346247Abstract: The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration.Type: ApplicationFiled: April 26, 2016Publication date: December 1, 2016Applicant: University of Notre Dame du LacInventors: Mayland CHANG, Shahriar MOBASHERY, Mijoon LEE
-
Patent number: 9321754Abstract: The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration.Type: GrantFiled: December 11, 2014Date of Patent: April 26, 2016Assignee: University of Notre Dame du LacInventors: Mayland Chang, Shahriar Mobashery, Mijoon Lee
-
Publication number: 20160031832Abstract: A new class of antibiotics effective against methicillin-resistant Staphylococcus aureus (MRSA) is disclosed. Compounds of this class can impair cell-wall biosynthesis by binding to both the allosteric and the catalytic domains of penicillin-binding protein (PBP) 2a. This class of antibiotics holds promise in reversing obsolescence of staphylococcal PBPs as important targets for antibiotics. Embodiments of the invention thus provide novel antibacterial compounds that target penicillin-binding proteins and/or other important cellular targets. Methods for inhibiting the growth and/or replication of bacteria using the compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, including drug-resistant strains of Staphylococcus aureus.Type: ApplicationFiled: March 5, 2014Publication date: February 4, 2016Applicant: University of Notre Dame Du LacInventors: Mayland CHANG, Shahriar MOBASHERY, Renee BOULEY
-
Patent number: 9045442Abstract: Embodiments of the present invention provide novel antibacterials that target penicillin-binding proteins or other important cellular targets. Methods for inhibiting growth (reproduction, etc.) of bacteria using compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, such as certain strains of Entercoccus and Staphylococcus aureus.Type: GrantFiled: December 21, 2007Date of Patent: June 2, 2015Assignee: University of Notre Dame du LacInventors: Shahriar Mobashery, Peter I. O'Daniel, Mayland Chang
-
Publication number: 20150093372Abstract: The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration.Type: ApplicationFiled: December 11, 2014Publication date: April 2, 2015Applicant: UNIVERSITY OF NOTRE DAME DU LACInventors: Mayland Chang, Shahriar Mobashery, Mijoon Lee
-
Publication number: 20150031663Abstract: The invention provides antimicrobial compounds and compositions, and methods of using them. The compounds and compositions include, for example, a compound of any one of Formulas I-X. The invention further provides methods of preparing the compounds, and useful intermediates for their preparation. The compounds can possess highly specific and selective activity, such as antibacterial activity and/or enzymatic inhibitory activity. Accordingly, the compounds and compositions can be used to treat bacterial infections, or to inhibit or kill bacteria, either in vitro or in vivo.Type: ApplicationFiled: October 13, 2014Publication date: January 29, 2015Applicant: UNIVERSITY OF NOTRE DAME DU LACInventors: Shahriar Mobashery, Dusan Hesek, Mayland Chang
-
Patent number: 8937151Abstract: The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration.Type: GrantFiled: March 4, 2011Date of Patent: January 20, 2015Assignee: University of Notre Dame du LacInventors: Mayland Chang, Shahriar Mobashery, Mijoon Lee
-
Patent number: 8859620Abstract: The invention provides antimicrobial compounds and compositions, and methods of using them. The compounds and compositions include, for example, a compound of any one of Formulas I-X. The invention further provides methods of preparing the compounds, and useful intermediates for their preparation. The compounds can possess highly specific and selective activity, such as antibacterial activity and/or enzymatic inhibitory activity. Accordingly, the compounds and compositions can be used to treat bacterial infections, or to inhibit or kill bacteria, either in vitro or in vivo.Type: GrantFiled: August 31, 2010Date of Patent: October 14, 2014Assignee: University of Notre Dame du LacInventors: Shahriar Mobashery, Dusan Hesek, Mayland Chang
-
Publication number: 20130064878Abstract: The invention provides a method of accelerating the healing process of a skin or subdermal wound. The method can include administering to a mammal afflicted with a skin or subdermal wound an effective amount of a gelatinase inhibitor, or a pharmaceutically acceptable salt thereof, wherein the gelatinase inhibitor is effective to accelerate the healing process of the skin wound. The method is particularly effective when the mammal is suffering from diabetes. The gelatinase inhibitor can be topically administered, for example, in the form of a cream, gel, lotion, ointment, salve, or solution.Type: ApplicationFiled: August 13, 2012Publication date: March 14, 2013Applicant: UNIVERSITY OF NOTRE DAME DU LACInventors: Mayland Chang, Mark A. Suckow, Shahriar Mobashery
-
Publication number: 20130052184Abstract: The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration.Type: ApplicationFiled: March 4, 2011Publication date: February 28, 2013Applicant: UNIVERSITY OF NOTRE DAME DU LACInventors: Mayland Chang, Shahriar Mobashery, Mijoon Lee
-
Publication number: 20120232150Abstract: The invention provides antimicrobial compounds and compositions, and methods of using them. The compounds and compositions include, for example, a compound of any one of Formulas I-X. The invention further provides methods of preparing the compounds, and useful intermediates for their preparation. The compounds can possess highly specific and selective activity, such as antibacterial activity and/or enzymatic inhibitory activity. Accordingly, the compounds and compositions can be used to treat bacterial infections, or to inhibit or kill bacteria, either in vitro or in vivo.Type: ApplicationFiled: August 31, 2010Publication date: September 13, 2012Inventors: Shahriar Mobashery, Dusan Hesek, Mayland Chang
-
Patent number: 8093287Abstract: The present invention provides novel compounds of formulas I-IX, as described herein. Also provided are compositions of compounds of formulas I-IX, methods of making compounds of formulas I-IX, and methods of using compounds of formulas I-IX. The compounds of the invention can be used to inhibit matrix metalloproteinases, and are useful to treat conditions and diseases associated therewith.Type: GrantFiled: March 14, 2011Date of Patent: January 10, 2012Assignees: University of Notre Dame du Lac, Wayne State UniversityInventors: Mijoon Lee, Masahiro Ikejiri, Mayland Chang, Rafael Fridman, Shahriar Mobashery
-
Publication number: 20110224275Abstract: The present invention provides novel compounds of formulas I-IX, as described herein. Also provided are compositions of compounds of formulas I-IX, methods of making compounds of formulas I-IX, and methods of using compounds of formulas I-IX. The compounds of the invention can be used to inhibit matrix metalloproteinases, and are useful to treat conditions and diseases associated therewith.Type: ApplicationFiled: March 14, 2011Publication date: September 15, 2011Applicants: NOTRE DAME UNIVERSITY, WAYNE STATE UNIVERSITYInventors: Mijoon Lee, Masahiro Ikejiri, Mayland Chang, Rafael Fridman, Shahriar Mobashery
-
Patent number: 7928127Abstract: The present invention provides novel compounds of formulas I-IX, as described herein. Also provided are compositions of compounds of formulas I-IX, methods of making compounds of formulas I-IX, and methods of using compounds of formulas I-IX. The compounds of the invention can be used to inhibit matrix metalloproteinases, and are useful to treat conditions and diseases associated therewith.Type: GrantFiled: May 19, 2006Date of Patent: April 19, 2011Assignees: Notre Dame University, Wayne State UniversityInventors: Mijoon Lee, Masahiro Ikejiri, Mayland Chang, Rafael Fridman, Shahriar Mobashery
-
Publication number: 20100261673Abstract: Embodiments of the present invention provide novel antibacterials that target penicillin-binding proteins or other important cellular targets. Methods for inhibiting growth (reproduction, etc.) of bacteria using compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, such as certain strains of Entercoccus and Staphylococcus aureus.Type: ApplicationFiled: December 21, 2007Publication date: October 14, 2010Applicant: UNIVERSITY OF NOTRE DAME DU LACInventors: Shahriar Mobashery, Peter I. O'Daniel, Mayland Chang
-
Publication number: 20090005420Abstract: The present invention provides novel compounds of formulas I-IX, as described herein. Also provided are compositions of compounds of formulas I-IX, methods of making compounds of formulas I-IX, and methods of using compounds of formulas I-IX. The compounds of the invention can be used to inhibit matrix metalloproteinases, and are useful to treat conditions and diseases associated therewith.Type: ApplicationFiled: May 19, 2006Publication date: January 1, 2009Inventors: Mijoon Lee, Masahiro Ikejiri, Mayland Chang, Rafael Fridman, Shahriar Mobashery